Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Healius Temettü

Temettü kriter kontrolleri 0/6

Healius şu anda temettü ödemiyor.

Anahtar bilgiler

Temettü verimi

Ödeme oranı

Sektör ortalama getirisi	2.7%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	AU$0.160
Hisse başına kazanç	-AU$0.88
Temettü verim tahmini	2.3%

Son temettü güncellemeleri

Healius (ASX:HLS) Is Paying Out A Larger Dividend Than Last Year

Feb 25

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: HLS şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: HLS şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Healius Piyasaya Karşı Temettü Getirisi

HLS temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (HLS)	0%
Pazarın Alt %25'i (AU)	2.6%
Pazarın En İyi %25'i (AU)	6.0%
Sektör Ortalaması (Healthcare)	2.7%
Analist tahmini (HLS) (3 yıla kadar)	2.3%

Önemli Temettü: HLS şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, HLS şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: HLS Australian piyasası için dikkate değer bir temettü ödemiyor.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: HLS herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Healius Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Healius Limited Announces Fully Franked Ordinary Paid Dividend for the Six Months Ended June 30, 2022, Payable on September 21, 2022

Upcoming dividend of AU$0.10 per share

Healius (ASX:HLS) Is Paying Out A Larger Dividend Than Last Year

Healius Limited Announces Ordinary Fully Paid Dividend for the Period of Six Months December 31, 2021, Payable April 15, 2022

Upcoming dividend of AU$0.068 per share

Recent updates

Price target increased by 14% to AU$1.77

Affinity Equity Partners (Australia) Pty Limited entered into a binding agreement to acquire Lumus Imaging from Healius Limited (ASX:HLS) for enterprise value of AUD 965 million.

Price target increased by 8.4% to AU$1.68

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Healius Limited, Annual General Meeting, Nov 15, 2024

Price target increased by 7.5% to AU$1.51

Full year 2024 earnings: Revenues exceed analyst expectations

TPG Capital, PEP Reportedly Still Competing for Healius Lumus Imaging

Final Bids Reportedly Expected for Healius

Healius Limited Announces Step Down of Ravi Jeyaraj as Non-Executive Director, Effective 2 August 2024

Macquarie Unit Reportedly in Healius Race

Healius Limited to Report Fiscal Year 2024 Results on Aug 21, 2024

Sonic in the Running for Healius Imaging Business

Private Equity Reportedly Eyes Healius Diagnostic Imaging Unit

High number of new directors

Healius Limited to Report First Half, 2024 Results on Feb 27, 2024

Australian Clinical Labs Limited (ASX:ACL) cancelled the acquisition of Healius Limited (ASX:HLS) from Tanarra Capital Australia Pty Ltd, Perpetual Investment Management Ltd and others.

New minor risk - Shareholder dilution

Interim Non-Executive Independent Chair recently bought AU$81k worth of stock

High number of new directors

Healius Limited Appoints Ravi Jeyaraj as Director

Healius Limited Announces Chair Changes

Healius Limited Announces Chair Changes

Healius Limited has filed a Follow-on Equity Offering in the amount of AUD 187.32 million.

Healius Limited has filed a Follow-on Equity Offering in the amount of AUD 187.32 million.

Healius Limited, Annual General Meeting, Nov 01, 2023

Australian Clinical Labs Limited (ASX:ACL) canceled the acquisition of Healius Limited (ASX:HLS)

Healius Limited Appoints Michael Stanford as Director

Full year 2023 earnings: Revenues miss analyst expectations

Healius Limited to Report Fiscal Year 2023 Results on Aug 30, 2023

Consensus EPS estimates fall by 37%

Consensus EPS estimates fall by 37%

Healius Limited Appoints Jan Van Rooyen as Group Executive, Healius Pathology Effective 1 June 2023

Consensus EPS estimates increase by 34%

Consensus EPS estimates increase by 36%

Consensus EPS estimates increase by 22%

High number of new directors

Consensus EPS estimates increase by 18%

Is Healius Limited (ASX:HLS) Trading At A 50% Discount?

Independent Non Executive Chairman recently bought AU$103k worth of stock

First half 2023 earnings released: AU$0.045 loss per share (vs AU$0.40 profit in 1H 2022)

Consensus EPS estimates increase by 17%

Healius Limited Announces Resignation of Alison Stephenson as Company Secretary

Consensus EPS estimates fall by 21%

At AU$3.07, Is It Time To Put Healius Limited (ASX:HLS) On Your Watch List?

Healius Limited to Report First Half, 2023 Results on Feb 27, 2023

Consensus forecasts updated

Price target decreased to AU$3.23

Consensus EPS estimates fall by 13%

Nexus Hospitals entered into an agreement to acquire Montserrat Healthcare Pty Ltd from Healius Limited (ASX:HLS).

Here's Why Healius (ASX:HLS) Can Manage Its Debt Responsibly

Consensus EPS estimates fall by 27%

QIC Reportedly Set to Clinch Healius Day Hospital Unit for $140 Million Plus

MD, CEO & Director recently sold AU$660k worth of stock

Is Now An Opportune Moment To Examine Healius Limited (ASX:HLS)?

Brookfield Reportedly Drops Out of Race to Buy Healius

Independent Non Executive Director recently bought AU$86k worth of stock

Non Executive & Independent Director recently bought AU$70k worth of stock

MD, CEO & Director exercised options to buy AU$2.2m worth of stock.

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Healius Limited Announces Fully Franked Ordinary Paid Dividend for the Six Months Ended June 30, 2022, Payable on September 21, 2022

Healius Limited, Annual General Meeting, Oct 20, 2022

Are Investors Undervaluing Healius Limited (ASX:HLS) By 48%?

Healius Reportedly Launches Day Surgery Sale Process

Price target decreased to AU$4.30

Healius Reportedly Keeps Watching Brief on Integral Diagnostics

Consensus EPS estimates fall by 13%

Healius Limited to Report Fiscal Year 2022 Results on Aug 31, 2022

Why Healius Limited (ASX:HLS) Could Be Worth Watching

Healius Reportedly Seeks X-Ray Factor in Day Surgeries Sale Plan